pipeline, revenue growth, and recent developments on an exclusive call with CEO Dr. Gary Jacob this Thursday, September 26, at 4 pm ET. Dr. Jacob will give a 15-minute presentation and then the call will be opened to questions from the audience.
Call information:
Sept. 26 at 4 pm ET /1 pm PT
Conference Line: (866) 821-0302**
**U.S. only. Contact us at info@redchip.com for dial-in info for investors outside U.S.
The Background: IMRN is an Australian biopharma focused on developing and commercializing orally delivered polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The Company currently markets Travelan in Australia, Canada, and the U.S. IMRN’s lead clinical drug candidate, IMM-124E, is presently in Phase II trials in severe alcoholic hepatitis (ASH) and pediatric non-alcoholic fatty liver disease (NAFLD), and the Company recently announced plans to pursue clinical development of IMM-124E through a formal FDA registration pathway as a drug to specifically prevent travelers’ diarrhea. IMRN’s second clinical-stage asset, IMM-529, targets Clostridium difficile infections (CDI), and is presently in a clinical trial in CDI patients. The Company is expected to file an IND with the FDA in the near-term targeting treatment of recurrent CDI.
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
News 
Market Data 
Discover 
